Guggenheim Capital LLC acquired a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 106,094 shares of the biopharmaceutical company’s stock, valued at approximately $1,177,000.
Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Van ECK Associates Corp increased its stake in Amicus Therapeutics by 48.9% during the fourth quarter. Van ECK Associates Corp now owns 2,988 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 981 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Amicus Therapeutics by 33.4% during the first quarter. China Universal Asset Management Co. Ltd. now owns 3,807 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 953 shares during the period. First Horizon Advisors Inc. increased its stake in Amicus Therapeutics by 37.3% during the fourth quarter. First Horizon Advisors Inc. now owns 3,856 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 1,048 shares during the period. Point72 Middle East FZE purchased a new stake in Amicus Therapeutics during the fourth quarter worth about $81,000. Finally, Neo Ivy Capital Management acquired a new position in shares of Amicus Therapeutics during the fourth quarter worth about $121,000.
Amicus Therapeutics Stock Performance
Shares of FOLD opened at $12.92 on Friday. The stock has a 50 day moving average price of $12.94 and a 200 day moving average price of $12.27. The company has a quick ratio of 2.40, a current ratio of 2.72 and a debt-to-equity ratio of 3.53. The company has a market capitalization of $3.71 billion, a price-to-earnings ratio of -20.19 and a beta of 0.84. Amicus Therapeutics, Inc. has a 52-week low of $9.10 and a 52-week high of $14.10.
Wall Street Analyst Weigh In
Separately, StockNews.com downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, Amicus Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.20.
Insider Buying and Selling at Amicus Therapeutics
In other Amicus Therapeutics news, Chairman John F. Crowley sold 6,044 shares of the business’s stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $13.04, for a total value of $78,813.76. Following the completion of the sale, the chairman now owns 950,273 shares in the company, valued at $12,391,559.92. The sale was disclosed in a document filed with the SEC, which is available through this link. In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 11,700 shares of the company’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $12.31, for a total value of $144,027.00. Following the sale, the chief executive officer now owns 815,154 shares of the company’s stock, valued at $10,034,545.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman John F. Crowley sold 6,044 shares of the company’s stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $13.04, for a total value of $78,813.76. Following the completion of the sale, the chairman now directly owns 950,273 shares in the company, valued at approximately $12,391,559.92. The disclosure for this sale can be found here. Over the last quarter, insiders sold 108,629 shares of company stock worth $1,445,385. 2.10% of the stock is owned by insiders.
Amicus Therapeutics Profile
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.
- Five stocks we like better than Amicus Therapeutics
- Stock Average Calculator
- MarketBeat Week in Review – 8/28 – 9/1
- Why Invest in 5G? How to Invest in 5G Stocks
- 2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Toyota vs Tesla: The Tortoise And The Hare Race Has A New Meaning
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.